ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,039.31
-0.47%
US Tech 100
20,882.00
0.05%
Dow Jones
44,713.52
-0.31%
Brent Oil
75.61
-0.41%
Bitcoin
105,280.49
1.49%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Kiniksa Pharmaceuticals International PLC (KNSA) Quote

Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International PLC (KNSA)

NASDAQ
20.66
0.48
(2.38%)
Closed January 30 4:00PM
Delayed by 15 minutes
20.66
0.00
(0.00%)
After Hours: 5:30PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
20.66
Bid
17.60
Ask
28.25
Volume
535,588
20.24 Day's Range 20.89
16.56 52 Week Range 28.15
Market Cap
1.492B
Previous Close
20.18
Open
20.24
Last Trade
1
@
20.26
Last Trade Time
Financial Volume
$ 11,013,924
VWAP
20.5642
Average Volume (3m)
397,769
Shares Outstanding
72,201,565
Dividend Yield
-
PE Ratio
105.89
Earnings Per Share (EPS)
0.2
Revenue
270.26M
Net Profit
14.08M

About Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurre... Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kiniksa.com
Headquarters
London, Gbr
Founded
-
Kiniksa Pharmaceuticals International PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KNSA. The last closing price for Kiniksa Pharmaceuticals was $20.18. Over the last year, Kiniksa Pharmaceuticals shares have traded in a share price range of $ 16.56 to $ 28.15.

Kiniksa Pharmaceuticals currently has 72,201,565 shares outstanding. The market capitalization of Kiniksa Pharmaceuticals is $1.46 billion. Kiniksa Pharmaceuticals has a price to earnings ratio (PE ratio) of 105.89.

Ask ADVFN Intelligence (AI)

Kiniksa Pharmaceuticals (KNSA) Options Flow Summary

KNSA Options Flow

Overall Flow

Bearish

Net Premium

-21k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

KNSA Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

January 15 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

January 13 2025
Edgar (US Regulatory)

Form 8-K - Current report

January 13 2025
Edgar (US Regulatory)

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

– ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net product revenue expected to be $560 - $580 million ––...

January 13 2025
GlobeNewswire Inc.

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on...

January 06 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

December 18 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

December 16 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 10 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 05 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

December 03 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.8810.010649627318.7820.918.4777663920.14039258CS
40.663.32020.917.8258511419.50155968CS
12-2.24-9.7816593886522.923.51517.8239776920.43663493CS
26-5.43-20.812571866626.0928.1517.8238710923.10139638CS
522.2812.404787812818.3828.1516.5639669721.63755973CS
1569.6988.331814038310.9728.157.3638896016.63230029CS
2605.5937.093563370915.07337.3639112316.65582729CS

KNSA - Frequently Asked Questions (FAQ)

What is the current Kiniksa Pharmaceuticals share price?
The current share price of Kiniksa Pharmaceuticals is $ 20.66
How many Kiniksa Pharmaceuticals shares are in issue?
Kiniksa Pharmaceuticals has 72,201,565 shares in issue
What is the market cap of Kiniksa Pharmaceuticals?
The market capitalisation of Kiniksa Pharmaceuticals is USD 1.46B
What is the 1 year trading range for Kiniksa Pharmaceuticals share price?
Kiniksa Pharmaceuticals has traded in the range of $ 16.56 to $ 28.15 during the past year
What is the PE ratio of Kiniksa Pharmaceuticals?
The price to earnings ratio of Kiniksa Pharmaceuticals is 105.89
What is the cash to sales ratio of Kiniksa Pharmaceuticals?
The cash to sales ratio of Kiniksa Pharmaceuticals is 5.52
What is the reporting currency for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Kiniksa Pharmaceuticals?
The latest annual turnover of Kiniksa Pharmaceuticals is USD 270.26M
What is the latest annual profit for Kiniksa Pharmaceuticals?
The latest annual profit of Kiniksa Pharmaceuticals is USD 14.08M
What is the registered address of Kiniksa Pharmaceuticals?
The registered address for Kiniksa Pharmaceuticals is THIRD FLOOR, 23 OLD BOND STREET, LONDON, W1S 4PZ
What is the Kiniksa Pharmaceuticals website address?
The website address for Kiniksa Pharmaceuticals is www.kiniksa.com
Which industry sector does Kiniksa Pharmaceuticals operate in?
Kiniksa Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DGNXDiginex Ltd
$ 49.18
(228.09%)
3.34M
SLXNSilexion Therapeutics Corporation
$ 3.1301
(131.86%)
330.45M
KRKR36Kr Holdings Inc
$ 9.10
(114.12%)
23.61M
SPGCSacks Parente Golf Inc
$ 0.6001
(57.92%)
52.17M
XFORX4 Pharmaceuticals Inc
$ 0.7542
(56.54%)
42.5M
ZKINZK International Group Co Ltd
$ 0.4813
(-41.21%)
3.1M
MGOLMGO Global Inc
$ 0.1019
(-38.73%)
70.52M
BACKIMAC Holdings Inc
$ 0.7869
(-35.50%)
2.37M
EYENEyenovia Inc
$ 0.03695
(-35.18%)
25.31M
HAOHaoxi Health Technology Ltd
$ 2.52
(-31.89%)
484.94k
NVDANVIDIA Corporation
$ 123.70
(-4.10%)
466.94M
SLXNSilexion Therapeutics Corporation
$ 3.1301
(131.86%)
330.45M
OCEAOcean Biomedical Inc
$ 0.249929
(-24.26%)
186.52M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.428
(-6.98%)
148.12M
RIMEAlgorhythm Holdings Inc
$ 0.0259
(-16.18%)
138.96M

KNSA Discussion

View Posts
Monksdream Monksdream 4 months ago
KNSA inching back up
👍️0
DonDonDonDon DonDonDonDon 4 years ago
No bueno. I guess HGEN's lenzilumab is the best of the anti-GM-CSF drugs for Covid. Lenzilumab's trial showed 54% efficacy. It is guaranteed an EUA within a couple of weeks yet its stock is 20% below where it was a month ago. It dropped 2 days ago because they diluted 5 million shares to pay for manufacturing.

https://www.rheumatologyadvisor.com/home/general-rheumatology/mavrilimumab-outcomes-patients-with-severe-covid19-pneumonia-hyperinflammation/
👍️0
DonDonDonDon DonDonDonDon 4 years ago
It was recently discovered that the protein GM-CSF is the cytokine responsible for severe Covid and death. Kiniksa will surely get a government grant to do an additional trial. Here is a BBC article about the trial that determined that GM-CSF is key to Covid:

https://www.bbc.com/news/health-56352128

Here is an additional article stating that KNSA and HGEN are the two companies with the best GM-CSF drugs to combat Covid:

https://www.clinicaltrialsarena.com/comment/humanigens-and-kiniksas-anti-gm-csf-antibodies-likely-to-garner-a-place-for-nonventilated-covid-19-patients/
👍️0
Femto99 Femto99 4 years ago
PT= $30-40 (by or around March 31st)
https://msmoneymoves.com/2021/02/17/knsa-report/
👍️0
Femto99 Femto99 4 years ago
PDUFA Mar21
👍️0

Your Recent History

NASDAQ
KNSA
Kiniksa Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads